Literature DB >> 21821496

SEOM guidelines on thrombosis in cancer patients.

Andrés J Muñoz1, Nuria Viñolas, Ricardo Cubedo, Dolores Isla.   

Abstract

The association between cancer and thrombosis is well established. Venous thromboembolism (VTE) is considered a main cause of mortality and morbidity in cancer patients and is commonly underestimated by oncologists. In recent years the incidence rates of VTE have notably increased. Several studies have clearly shown that cancer patients who are diagnosed with VTE present a poorer prognosis. The Spanish Society of Medical Oncology (SEOM) presents the guidelines for thrombosis and cancer in order to improve the prevention and management of VTE.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21821496     DOI： 10.1007/s12094-011-0703-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  26 in total

1.  A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project.

Authors:  Giancarlo Agnelli; Giorgio Bolis; Lorenzo Capussotti; Roberto Mario Scarpa; Francesco Tonelli; Erminio Bonizzoni; Marco Moia; Fabio Parazzini; Romina Rossi; Francesco Sonaglia; Bettina Valarani; Carlo Bianchini; Gualberto Gussoni
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

2.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

Authors:  Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing
Journal:  BMJ       Date:  2006-01-26

Review 3.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

4.  Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.

Authors:  Steven R Deitcher; Craig M Kessler; Geno Merli; James R Rigas; Roger M Lyons; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2006-10       Impact factor: 2.389

5.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

6.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

7.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

Review 8.  Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction).

Authors:  Raza Alikhan; Alexander T Cohen
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

9.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.

Authors:  Guy Meyer; Zora Marjanovic; Judith Valcke; Bernard Lorcerie; Yves Gruel; Philippe Solal-Celigny; Christine Le Maignan; Jean Marc Extra; Paul Cottu; Dominique Farge
Journal:  Arch Intern Med       Date:  2002 Aug 12-26

Review 10.  Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

Authors:  Alok A Khorana; Michael B Streiff; Dominique Farge; Mario Mandala; Philippe Debourdeau; Francis Cajfinger; Michel Marty; Anna Falanga; Gary H Lyman
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  2 in total

Review 1.  Safety and efficacy of primary thromboprophylaxis in cancer patients.

Authors:  I García Escobar; M Antonio Rebollo; S García Adrián; A Rodríguez-Garzotto; A Muñoz Martín
Journal:  Clin Transl Oncol       Date:  2016-05-04       Impact factor: 3.405

2.  Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.

Authors:  A J Muñoz Martín; P García Alfonso; A B Rupérez Blanco; S Pérez Ramírez; M Blanco Codesido; M Martín Jiménez
Journal:  Clin Transl Oncol       Date:  2014-03-19       Impact factor: 3.405
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.